Navidea Biopharmaceuticals has patented a method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone. The process ensures the complex is free of crosslinking, offering potential applications in medical imaging and drug delivery. GlobalData’s report on Navidea Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Navidea Biopharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Navidea Biopharmaceuticals, Isotropically modified heterocyclic compounds was a key innovation area identified from patents. Navidea Biopharmaceuticals's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Method for conjugating metal chelating agent to functionalized dextran

Source: United States Patent and Trademark Office (USPTO). Credit: Navidea Biopharmaceuticals Inc

A recently granted patent (Publication Number: US11859023B2) discloses a method for conjugating a metal chelating agent to a functionalized dextran. The process involves reacting a chelator with an aminated dextran backbone, where the chelator has carboxylic acid groups, with only one group activated to form a chelator-dextran complex. The dextran-chelator complex is free of intra- or intermolecular crosslinking, ensuring structural integrity.

Furthermore, the patent details a method for synthesizing an amine dextran by adding mannose moieties to the chelator-dextran complex through amidate linkage. The protecting groups conjugated to the carboxylic acid groups are removed, allowing for the addition of mannose moieties. The chelator used in this process can be DTPA or DOTA, with various protecting groups like t-butyl esters or benzyl esters employed to facilitate the synthesis. This innovative method offers a precise and efficient way to create functionalized dextrans for various applications in the field of metal chelation and drug delivery.

To know more about GlobalData’s detailed insights on Navidea Biopharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies